Table 4.
Plasma concentration of antiretroviral drugs in a sample of patients who started TDF-FTC+ZDV (n=25)
| Upper gastrointestinal adverse event within first month of treatment | |||
|---|---|---|---|
| No (n=4) | Yes (n=21) | p | |
| ZDV Cmax (ng/ml), median (IQR) | 1294 (735–1870) | 1184 (831–1486) | 0.50 |
| G-ZDV Cmax (ng/ml), median (IQR) | 9258 (6787–13604) | 7054 (5071–8956) | 0.24 |
| Tenofovir, median (IQR) | |||
| Cmin (ng/ml) | 48 (28–77) | 64 (26–88) | 0.74 |
| Cmax (ng/ml) | 39 (29–59) | 60 (29–85) | 0.48 |
ZDV: zidovudine; G-ZDV: Glucuronide metabolite of ZDV; Cmin (minimum concentration): Measured before pill intake; Cmax (maximum concentration): Measured 1 hour after ZDV pill intake; IQR: interquartile range; ng/ml: nanograms per millimetre.